Are you developing the next generation of therapeutic antibodies?
You know then that it's often difficult to evaluate Fc effector activities and determine which of these effects is prevalent in the mode of action in a rapid, reliable, robust, and reproducible way. Here, you can learn more about the relevance of antibody-induced complement‐dependent cytotoxicity (CDC) and how to measure the potency of CDC induction or inhibition using an advanced functional bioassay that goes beyond interaction to support biologics development.
Dive deep into cutting-edge therapeutic antibody development with our latest whitepaper, now available for download.